Wyeth-Ayerst Antidepressant (serotonin/ norepinephrine reuptake inhibitor) 14.
In other countries (eg, South Africa), the generic Effexor XR
came out even earlier and one generic company, Ciplo Medpro  , are already legally manufacturing and selling extended release venlafaxine capsules under the brand name Venlor XR in that country.
In the study, 69 percent or more of patients treated with Effexor XR
showed significant improvements in symptoms of GAD for up to six months, compared with 42 to 46 percent given a placebo.
The most common adverse events reported in EFFEXOR XR
short-term placebo-controlled depression trials and EFFEXOR XR
short-term placebo-controlled depression, generalized anxiety disorder (GAD), and/or social anxiety disorder trials (incidence greater than or equal to 10% and greater than or equal to 2x that of placebo) were anorexia, asthenia, constipation, dizziness, dry mouth, ejaculation problems, impotence, insomnia, nausea, nervousness, somnolence, and sweating.
The two randomized, double-blind, placebo-controlled trials evaluated the short- and long-term efficacy and safety of Effexor XR
in treating symptoms of GAD.
During Jim's tenure leading Wyeth Canada, sales more than doubled to over $650 million in less than four years, and all key promoted brands including Effexor XR
, Prevnar, Enbrel, Alesse, Premarin and BeneFix achieved the #1 market share position in each of their respective categories.
Prescriptions for venlafaxine "should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose," according to the revised label or prescribing information for Effexor and Effexor XR
The study was funded by Wyeth Research, the parent company of which distributes venlafaxine XR under the brand name Effexor XR
The trial was funded by Wyeth Research, which markets Effexor XR
The depression therapeutics market will face the patent expiry of leading drugs such as Lexapro (2012), Cymbalta (2013) and Effexor XR
The Pharmacor advisory service entitled Unipolar Depression finds that major-market sales in the unipolar depression market will decline by 30 percent from 2012-2022 owing to the generic entry of the blockbuster drugs escitalopram (Lundbeck's Cipralex/Seroplex, other manufacturers, Forest Laboratories' Lexapro, generics; Lundbeck/Mochida Pharmaceuticals/Mitsubishi Tanabe Pharma's Lexapro), Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify and Eli Lilly/Shionogi's Cymbalta/Xeristar, as well as expanded generic competition for venlafaxine XR (Pfizer/Almirall's Effexor XR
, other manufacturers, generics).
All 33 randomized trials and the pooled analysis were funded by Wyeth Pharmaceuticals, which markets venlafaxine as Effexor XR